Namenda

This page shows the latest Namenda news and features for those working in and with pharma, biotech and healthcare.

Forest said to be interested in $3bn Aptalis acquisition

US for former blockbuster antidepressant Lexapro (escitalopram), as well as generic competition from 2015 for Alzheimer's disease therapy Namenda (memantine). ... With Lexapro and Namenda accounting for more than three quarters of company turnover at

Latest news

Lundbeck and Otsuka take Alzheimer's drug into phase III

Regardless, it has been 10 years since the last new Alzheimer's treatment reached the market - Lundbeck's glutamate (NMDA) antagonist Ebixa (memantine), which is sold as Namenda by Forest Labs
Lexapro generics hammer Forest Labs' Q3 results

On the plus side, Alzheimer's drug Namenda (memantine) achieved a 9 per cent hike in sales to $368m, while antihypertensive Bystolic (nebivolol) was up almost 30 per cent to $106m. ... With Lexapro now completely genericised we have a bright future with
Forest's net income down for Q3

He said: "We have been working diligently for the past seven years to build a solid product development pipeline that will more than replace the loss of Lexapro and Namenda following
Forest Laboratories earnings rise

Lexapro (escitalopram) and its Alzheimer's drug Namenda (memantine) lose their patent protection in the coming years. ... expiration for both Lexapro in 2012 and Namenda in 2015 and provide growth," he said.
Lifting the fog

Additionally, a patch formulation of donepezil is in development. Also approved for the treatment of moderate-to-severe AD is memantine (Namenda, Forest Laboratories), which was the first NMDA receptor antagonist

More from news
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest Intelligence

Pharma deals during January 2014

Not disclosed. Adamas. Forest. Completion of studies for the NDA of a fixed dosed combination of Namenda and donepezil, Forest has exclusive US commercialisation rights.
Pharma deals during November 2012

Development / commercialisation. Fixed dose combination of Namenda and donepezil for AD.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Editorial Manager - MedComms: DOE

Principal Health Economist - North-West: Negotiable

Account Executive/ Senior Account Executive: competitive Salary Offfered

Healthcare Advertising Senior Account Manager / AD / Senior AD: Salary TBC

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Client Services Director – Medical Education Agency – North West...: Salary TBC

Systematic Reviewer - Oxford: Negotiable

Account Director – Healthcare Marketing – Berks: Salary TBC

Account Manager- Healthcare Advertising: Negotiable

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Account Director: Competitive Salary Offered

Business Director: Competitive Salary Offered

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Senior Editorial Assistant – Greater Manchester: DOE

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Business Development Director – Health Education: excellent commission

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Experienced Medical Writers: Competitive Salary and Benefits

Associate Director: £75, 000-90, 000

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Account Manager: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?: What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma: Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies: Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...